Head and Neck Squamous Cell Carcinoma (HNSCC) Clinical Trials

• Voluntarily participate and sign the informed consent form

• At least 18 years old, male or female

• Subjects with locally advanced/metastatic solid tumors confirmed by histology and/or cytology;

• Subjects in Part 1 should have at least one tumor lesion evaluable by RECIST v1.1 criteria, and subjects in Part 2 should have at least one measurable tumor lesion by RECIST v1.1 (lesions that have received radiotherapy or other local treatments cannot be used as target lesions unless there is clear progression of the lesion)

• Subjects with locally advanced/metastatic solid tumors who have failed standard treatment: Part 1: Subjects with solid tumors who have experienced disease progression during/after at least one previous standard systemic anti-tumor regimen and are not suitable for standard treatment. Part 2: Non-small cell lung cancer, liver cancer, head and neck squamous cell carcinoma, colorectal cancer that have experienced disease progression during/after at least one previous standard systemic anti-tumor regimen and are not suitable for standard treatment

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Expected survival period ≥ 12 weeks

• Adequate organ and bone marrow function

• Archived formalin-fixed, paraffin-embedded (FFPE) tumor tissue or fresh biopsy tissue within 5 years must be provided before the first administration